The FDA has approved Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. This approval is based on the AZUR-1 trial showing 68% of patients achieved complete clinical response after one year, with no cancer recurrence after two years median follow-up. Jemperli offers a treatment alternative that could help patients avoid chemotherapy, radiation, and surgery, which often cause lasting side effects. GSK will present full trial data at the ESMO Congress 2026, while regulatory reviews continue internationally.
GSK's market cap stands at $99.04 billion with a dividend yield of 3.67% as of Oct 20, 2026, 02:11 WIB. The stock price is USD 49.60, showing a modest 0.19% increase on the day. Trading volume on Pluang reached 6,917,324 shares, reflecting steady investor interest around the time of Jemperli's FDA approval news.
Jefferies has upgraded GSK PLC to a 'buy' rating with a 2,500p price target, suggesting a 34% gain from recent levels. This follows positive results from the EMBOLD trial of GSK's experimental lung cancer drug ris-rez, which showed a 61% tumor respon...
GSK announced that its experimental lung cancer drug, risvutatug rezetecan, achieved a 61% confirmed response rate at the higher 8 mg/kg dose in an early global trial involving patients with relapsed extensive-stage small cell lung cancer. This respo...
